Psyence Biomedical in Spotlight After Trump’s Ibogaine Order Puts Supply Strategy to the Test
Psyence Biomedical Ltd., which trades on the Nasdaq, caught attention after President Donald Trump signed an order on April 18 aimed at accelerating research into psychedelic drugs—including ibogaine, now under study for addiction and PTSD. Reuters market data showed shares of Psyence jumped 29.5% to $7.60 at the close on April 17, as the company reacted positively to news that Washington was set to act.
